|
Fasting PCSK9 and lipid levels pre- and post-fibrate treatment |
|||
| Baseline |
Treatment |
% Change |
|
|
|
|||
| PCSK9 (μg/mL) |
6.04 ± 1.10 |
6.90 ± 1.38* |
17.01 ± 29.5 |
| Total cholesterol |
6.22 ± 0.73 |
5.50 ± 0.88** |
-11.3 ± 11.6 |
| Triglycerides |
3.27 ± 0.59 |
1.85 ± 0.80*** |
-43.6 ± 22.8 |
| HDL cholesterol |
0.86 ± 0.13 |
1.00 ± 0.21** |
15.7 ± 18.4 |
| LDL cholesterol |
3.85 ± 0.65 |
3.65 ± 0.71 |
-4.22 ± 17.6 |
| TC/HDLC Ratio |
7.35 ± 1.22 |
5.79 ± 1.68*** |
-22.0 ± 13.5 |
|
Significance comparing baseline and treatment by Wilcoxon's signed rank test (n = 19). Values expressed as μmol/L except where indicated. *p < 0.05, **p < 0.001, ***p < 0.0001 | |||
Mayne et al. Lipids in Health and Disease 2008 7:22 doi:10.1186/1476-511X-7-22 |
|||